JNJ
New target, same swagger
Morgan Stanley just told Johnson & Johnson shareholders: yeah, we see the upside too. The firm lifted its price target to $283 from a prior level and reiterated its Overweight rating after J&J delivered a quarter that checked the two boxes the market loves most: beat earnings, raise guidance.
Why the Street is getting louder
The real tell here isn’t just the new target — it’s the math behind it. Morgan Stanley nudged up its 2026 EPS estimate to $11.82 from $11.73, and its 2027 estimate to $13.47 from $13.15. Then it slapped a 20.3x P/E multiple on its forward earnings view to land on that $283 target.
That’s Wall Street speak for: this isn’t a one-quarter sugar rush. The analysts think the business can keep grinding higher, and they’re willing to value it like a steadier, higher-quality compounder instead of a sleepy mega-cap healthcare name you only notice when the dividend lands.
Why you should care
When management raises guidance after Q1, it usually means it isn’t just crossing its fingers and hoping for the best. It’s signaling that the rest of the year still looks sturdy enough to tighten the range upward — which is exactly the kind of setup that gets analysts reaching for a more generous multiple.
Big picture: J&J’s not exactly a meme-stock rocket ship, but the Street is basically saying the old reliable giant still has room to flex. And in this market, boring can be beautiful.